| Grab Sources And More: HOTH Website. HOTH Presentation. -----
And based on the several potential catalysts I mentioned above, (Nasdaq: HOTH) is front and center on my radar. Check them out:
#1. HOTH Potential Catalyst - A Low Float Could Create A Scenario With Heightened Volatility Potential.
According to info from the Yahoo Finance website, HOTH has a low float.
In fact, the website reports this profile to have approximately 13.19Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If positive company news appears in the 2nd half of 2025, could it provide a breakout spark when paired with the potential volatility? -----
#2. HOTH Potential Catalyst - HOTH Engages With ICON To Expand Key Phase II Clinical Trial.
Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe
The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries
NEW YORK, July 29, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced its engagement with ICON Clinical Research Limited ("ICON") to expand it's Phase II Clinical Trial for cancer patients suffering from skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
Additional regulatory approval for the Phase II clinical trial is expected from potentially three EU countries in the upcoming months. The EU approval is part of the Company's international clinical development strategy for HT-001. The trial is currently enrolling patients in multiple sites in the United States. This Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi. ...
"We are delighted with the addition of clinical sites in the EU and for a strong partnership with ICON. ICON was selected based on their previous clinical trial management experience and their interest in novel therapies," said Robb Knie, CEO of Hoth Therapeutics. "Broadening the clinical presence in the EU serves dual purposes. First, it addresses the near-term objective of completing enrollment of the Phase II trial. Additionally, the initiation of sites in the EU establishes the groundwork for realizing our long-term goal of conducting a global Phase III trial."
Read the full article here. -----
#3. HOTH Potential Catalyst - A "Landmark" Agreement Will Help Evaluate GDNF's Metabolic Effects Alongside Semaglutide (The Current Gold Standard).
Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins
NEW YORK, July 22, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development Agreement) with the U.S. Department of Veterans Affairs and Foundation for Atlanta Veterans Education and Research (FAVER) to evaluate GDNF (glial cell-derived neurotrophic factor) as a novel metabolic therapy targeting obesity and hepatic steatosis (fatty liver disease).
The study, conducted at the Atlanta VA Medical Center, will benchmark daily GDNF injections against semaglutide in both standard diet-induced obese mice and human liver chimeric mouse models, a gold-standard translational platform.
...
This CRADA marks the first pharmacologic test of GDNF in human liver-engrafted mice — setting the stage for potential first-in-class metabolic applications beyond CNS indications.
"This landmark agreement allows a real-world, controlled comparison of GDNF's metabolic effects alongside semaglutide — the current gold standard," said Robb Knie, CEO of Hoth Therapeutics. "We are proud to support the VA's efforts in exploring bold new solutions for obesity and liver disease."
Read the full article here. -----
#4. HOTH Potential Catalyst - HOTH's Investigational Candidate HT-001 Meets At Least One Primary Efficacy Endpoint In Ongoing Phase 2a Clinical Study.
Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects
Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities.
...
Phase 2a Trial Highlights (CLEER-001)
100% of enrolled patients in open-label cohort achieved at least one primary endpoint of clinical dermatologic improvement
Over 65% reported reductions in pain and pruritus (itching)
0% required dose reduction or discontinuation of their EGFRI therapy.
Topical therapy was well tolerated with no serious adverse events.
NEW YORK, June 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing targeted therapies for rare and serious inflammatory conditions, today announced that its investigational candidate HT-001 met the primary efficacy endpoint in at least one metric in 100% of patients in its ongoing Phase 2a clinical study (CLEER-001) evaluating treatment for epidermal growth factor receptor inhibitor (EGFRI)-induced cutaneous toxicities.
EGFR inhibitors, used widely to treat non-small cell lung cancer (NSCLC), pancreatic, breast, colorectal, and head and neck cancers, are associated with dermatologic side effects in up to 90% of patients, often resulting in painful rashes, pruritus, dryness, nail changes, and alopecia. These adverse events frequently force dose reductions or treatment discontinuation, limiting therapeutic efficacy and patient outcomes.
"HT-001 is a breakthrough candidate with the potential to be the first FDA-approved therapy specifically targeting these EGFRI-related skin toxicities," said Robb Knie, CEO of Hoth Therapeutics. "The ability to preserve full-dose cancer treatment while improving patient quality of life addresses a critical unmet need across oncology."
...
Read the full article here. -----
#5. HOTH Potential Catalyst - Oversold Leaning Technical Indicators Suggest A Healthy Reversal/Bounce Situation Could Be Approaching.
At 4:00PM EST Friday, Barchart was reporting HOTH to have several oversold leaning technical indicators.
These technicals could be signaling a healthy reversal is approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Here's the technicals to pay close attention to (as of 4:00PM EST Friday):
- 9-Day Relative Strength Index: 31.39%
- 14-Day Relative Strength Index: 38.74%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic: 10.38%
As the Raw Stochastic nears the 10% range and lower it may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely. -----
(Nasdaq: HOTH) Recap - 5 Potential Catalysts Put This Profile On Radar Notice
#1. A Low Float Could Create A Scenario With Heightened Volatility Potential.
#2. HOTH Engages With ICON To Expand Key Phase II Clinical Trial.
#3. A "Landmark" Agreement Will Help Evaluate GDNF's Metabolic Effects Alongside Semaglutide (The Current Gold Standard).
#4. HOTH's Investigational Candidate HT-001 Meets At Least One Primary Efficacy Endpoint In Ongoing Phase 2a Clinical Study.
#5. Oversold Leaning Technical Indicators Suggest A Healthy Reversal/Bounce Situation Could Be Approaching. -----
Coverage is officially underway on Hoth Therapeutics, Inc. (Nasdaq: HOTH). When updates are available, I'll get them out quickly.
Talk soon.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 09/01/2025 and ending on 09/02/2025 to publicly disseminate information about (HOTH:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (HOTH:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/hoth-w3av3/#details | 
